NCT06552559
- Conditions
- B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, CNS Metastases
- Locations
-
- Samsung Cancer Research Institute Seoul, South Korea
- Samsung Medical Center Seoul, South Korea
Clinical trial condition
B-cell Lymphoma Refractory
Explore clinical trials studying B-cell Lymphoma Refractory. Study availability and eligibility vary by location and protocol.
13 public trials
5 recruiting studies
B-cell Lymphoma Refractory trial results
NCT07319676
- Conditions
- B-cell Lymphoma Refractory, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
- Locations
-
- National University Hospital Singapore
NCT07321301
- Conditions
- B-cell Lymphoma Refractory
- Locations
-
- Chinese PLA General Hospital Beijing, Beijing Municipality, China
NCT05705570
- Conditions
- Acute Lymphoblastic Leukemia Refractory, Acute Lymphoblastic Leukemia, in Relapse, B-cell Lymphoma Recurrent, +14 more
- Locations
-
- Hospital Israelita Albert Einstein São Paulo, Brazil
NCT06445803
- Conditions
- Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia, in Relapse, B-cell Lymphoma Recurrent, +12 more
- Locations
-
- The First Affiliated Hospital of Nanchang University; Nanchang, Jiangxi, China
- Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China
Not yet recruiting
Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma
NCT05909098
- Conditions
- B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, NK Cell
- Locations
-
- EC of Xiangyang No.1 People's Hospital Hubei University of Medicine Hubei, Xiangyang, China
Active, not recruiting
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
NCT03853616
- Conditions
- Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, +2 more
- Locations
-
- Charité - University clinic, pediatric clinic with focus on oncology and hematology Berlin, Germany
- Universitätsklinikum Erlangen Erlangen, Germany
- University medicine Goettingen, Clinic of hematology and medical oncology Göttingen, Germany
- Children's Hospital of Dr. von Hauner by Ludwig-Maximilian University Munich, Germany
Active, not recruiting
Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation
NCT04531046
- Conditions
- B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory
- Locations
-
- CH Liège Liège, Belgium
- CHU de Bordeaux - Hôpital Haut Lévêque Bordeaux, France
- CHU Clermont Ferrand - Hôpital Estaing Clermont-Ferrand, France
- APHP - Hôpital Henri Mondor Créteil, France
Active, not recruiting
Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies
NCT06220097
- Conditions
- B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory, Burkitt Lymphoma, +16 more
- Locations
-
- Union Hospital, Huazhong University of Science and Technology Wuhan, Hubei, China
Active, not recruiting
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies
NCT04214886
- Conditions
- B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, +19 more
- Locations
-
- Loyola University Maywood, Illinois, United States